1,348 reports of this reaction
3.6% of all AMIKACIN reports
#6 most reported adverse reaction
THERAPY INTERRUPTED is the #6 most commonly reported adverse reaction for AMIKACIN, manufactured by Insmed Incorporated. There are 1,348 FDA adverse event reports linking AMIKACIN to THERAPY INTERRUPTED. This represents approximately 3.6% of all 37,285 adverse event reports for this drug.
Patients taking AMIKACIN who experience therapy interrupted should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPY INTERRUPTED is moderately reported among AMIKACIN users, representing a notable but not dominant share of adverse events.
In addition to therapy interrupted, the following adverse reactions have been reported for AMIKACIN:
The following drugs have also been linked to therapy interrupted in FDA adverse event reports:
THERAPY INTERRUPTED has been reported as an adverse event in 1,348 FDA reports for AMIKACIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPY INTERRUPTED accounts for approximately 3.6% of all adverse event reports for AMIKACIN, making it a notable side effect.
If you experience therapy interrupted while taking AMIKACIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.